CLINICAL STUDIES OF BRL 28500 (CLAVULANIC ACID/TICARCILLIN) IN THE TREATMENT OF PELVIOPERITONITIS AND DOUGLAS' ABSCESS

Abstract

Clinical studies were conducted on BRL 28500 (a formulation containing 15 parts ticarcillin plus 1 part clavulanic acid). BRL 28500 was administered at doses of 1.6 g or 3.2 g b.i. d., generally for 10 days by drip infusion to patients with pelvioperitonitis or DOUGLAS' abscess.
The results obtained were summarized as follows.
1. Clinical efficacy was evaluated in 18 patients (pelvioperitonitis 14, DOUGLAS' abscess 4), but 8 patients out of a total of 26 patients were excluded.
2. In the evaluation of clinical improvement by doctors in charge, clinical improvement rates were 44.4% on day 3, 88.2% on day 5.
3. On the basis of committee judgement, the clinical efficacy rate was 100%.
4. The bacteriological eradication rate of causative organisms was 100% in 11 patients (15 strains). Five strains out of a total of 15 strains produced β-lactamase.
5. As a side effect, nausea was observed in 1 case. In laboratory examination, liver function abnormalities were observed in 1 case.
6. Regarding usefulness as judged by doctors in charge, the satisfactory rate was 83.3%.
From the above results, it has been concluded that BRL 28500 is very useful in the treatment of pelvioperitonitis and DOUGLAS' abscess.